Related Experiment Video
Updated: Dec 24, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series
Mohammad Hasan Namazi1, Farzam Saemifard1, Mehdi Pishgahi2
1Interventional Cardiology department, Shahid Modarres Heart Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Ticagrelor therapy after PCI showed one-month follow-up findings including dyspnea and bleeding. No bradycardia or thrombosis occurred, but 6.4% of patients discontinued the drug.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ticagrelor is a reversible oral P2Y12 receptor antagonist.
- It effectively inhibits ADP-induced platelet aggregation.
Purpose of the Study:
- To describe one-month follow-up outcomes in patients receiving ticagrelor post-percutaneous coronary intervention (PCI).
Main Methods:
- A case series of acute coronary syndrome (ACS) patients undergoing PCI.
- Patients received aspirin plus ticagrelor and were followed for one month.
Main Results:
- 156 patients studied; 28.8% experienced dyspnea, and 2.5% had bleeding events (including one intracranial hemorrhage).
- No bradycardia or thrombosis observed.
- 6.4% of patients discontinued ticagrelor due to adverse events like severe dyspnea, ICH, or rash.
Conclusions:
- One-month ticagrelor use was associated with dyspnea, bleeding, and hypersensitivity reactions.
- No bradycardia or stent thrombosis was detected.
- The Iranian population in this study showed higher susceptibility to dyspnea compared to PLATO trial results.
Introduction:
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist that can block ADP-induced platelet aggregation. This study aimed to describe one-month follow-up findings of cases undergoing ticagrelor therapy after percutaneous coronary intervention (PCI).
Methods:
This case series was performed on acute coronary syndrome (ACS) patients who were candidates for PCI and received aspirin plus ticagrelor after PCI. Patients were followed for one month and their outcomes were described.
Results:
156 cases with the mean age of 59.74 ± 9.24 years were studied (63% male). 45 (28.8%) cases complained of dyspnea (39 cases with mild and 6 cases with severe dyspnea). Bleeding occurred in 4 (2.5%) cases (intra-cranial hemorrhage (ICH) in one, hematuria in two, and skin hemorrhage in one case). There were no cases with bradycardia or thrombosis. One (0.6%) patient developed drug hypersensitivity reaction, which manifested as skin rash. The use of drug was stopped in 10 (6.4%) cases due to severe dyspnea (n= 6), ICH (n=1), skin rash (n=1), and concomitant left ventricular (LV) clot (n=2).
Conclusion:
The most important finding of one-month ticagrelor consumption were dyspnea, bleeding, and hypersensitivity reaction. No case of bradycardia and stent thrombosis was detected. In our study , iranian population has more susceptibility to dyspnea than PLATO result. The rate of drug discontinuation in this series of cases was 6.4 %.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
08:12Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care